Sensitivity of plasma BRAF(mutant) and NRAS(mutant) cell‐free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non‐RECIST disease progression

Melanoma lacks a clinically useful blood‐based biomarker of disease activity to help guide patient management. To determine whether measurements of circulating, cell‐free, tumor‐associated BRAFmutant and NRASmutant DNA (ctDNA) have a higher sensitivity than LDH to detect metastatic disease prior to...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Mol Oncol
Hauptverfasser: Chang, Gregory A., Tadepalli, Jyothirmayee S., Shao, Yongzhao, Zhang, Yilong, Weiss, Sarah, Robinson, Eric, Spittle, Cindy, Furtado, Manohar, Shelton, Dawne N., Karlin-Neumann, George, Pavlick, Anna, Osman, Iman, Polsky, David
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2015
Schlagworte:
Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4695284/
https://ncbi.nlm.nih.gov/pubmed/26440707
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2015.09.005
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge